TruGRAF: 25% of all transplanted kidneys can face silent rejection
Escape silent rejection, which can affect 25% of all transplanted kidneys*, by using TruGraf.
TruGraf® is a non-invasive blood test designed to assess kidney transplant rejection through gene expression profiling. It analyzes the expression of certain genes in the blood that are associated with immune responses, particularly those related to transplant rejection. TruGraf® is used to help detect subclinical or early-stage rejection, allowing healthcare providers to intervene earlier and more effectively manage kidney transplant recipients.
Key benefits of serial surveillance with TruGraf include:
- Patients avoid painful, risky, invasive procedures that are negative 75% of the time.
- Patients and their caregivers know that they don’t harbor “silent” subclinical rejection.
- Healthcare professionals can stratify patients into those who may benefit from surveillance biopsy and those who likely won’t, allowing them to eliminate unnecessary biopsies and focus interventions on patients experiencing rejection.
*Friedewald JJ, Kurian SM, Heilman RL, Whisenant TC, Poggio ED, Marsh C, Baliga P, Odim J, Brown MM, Ikle DN, Armstrong BD, Charette JI, Brietigam SS, Sustento-Reodica N, Zhao L, Kandpal M, Salomon DR, Abecassis MM; Clinical Trials in Organ Transplantation 08 (CTOT-08). Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant. Am J Transplant. 2019 Jan;19(1):98-109. doi: 10.1111/ajt.15011. Epub 2018 Aug 31. PMID: 29985559; PMCID: PMC6387870.
Value Proposition
25% of kidney transplant recipients suffer from silent rejection. TruGRAF kidney helps identify vulnerable recipients and prevent silent rejection.
Achievements
We work on exclusive basis with BioHope of Spain and Eurofin of the US.
